摘要
目的探讨布地奈德混悬液联合异丙托溴铵在慢性阻塞性肺疾病(COPD)患者中的应用效果及对肺功能的影响。方法选取2019年1月—12月安徽医科大学第四附属医院收治的COPD患者100例,将其按随机数字表法分为观察组和对照组,每组各50例。对照组采用布地奈德混悬液治疗,观察组采用布地奈德混悬液联合异丙托溴铵治疗,治疗10 d。比较两组治疗前及治疗10 d后肺功能[第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC],炎症因子[肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)],并记录体征、临床症状缓解时间、住院时间变化情况及不良反应发生情况。结果观察组住院时间、气促呼吸困难消失时间、肺部体征消失时间、喘憋消失时间、咳嗽缓解时间均明显短于对照组,差异均有统计学意义(均P<0.05);治疗后,观察组肺功能FEV1、FVC、FEV1/FVC水平均高于对照组,TNF-α、hs-CRP水平均低于对照组,差异均有统计学意义(均P<0.05)。结论联合用药对于COPD患者治疗效果显著,安全性高。
Objective To investigate the effect of Budesonide Suspension combined with Ipratropium Bromide in patients with chronic obstructive pulmonary disease(COPD)and its effect on lung function.Methods A total of 100 COPD patients admitted to the Fourth Affiliated Hospital of Anhui Medical University from January to December 2019 were selected and divided into observation group and control group according to random number table method,with 50 patients in each group.The control group was treated with Budesonide Suspension,and the observation group was treated with Budesonide Suspension combined with Ipratropium Bromide for 10 days.The lung function(forced expiratory volume in the first second[FEV1],forced vital capacity[FVC],FEV1/FVC),inflammatory factors(tumor necrosis factor-α[TNF-α],hypersensitivity C-reactive protein[hs-CRP])were compared between the two groups before treatment and 10 days after treatment,and the changes of signs,remission time of clinical symptoms,length of hospital stay and the incidence of adverse reactions were recorded.Results The length of hospital stay,disappearance time of shortness of breath and dyspnea,disappearance time of lung signs,disappearance time of asthma and relief time of cough in the observation group were significantly shorter than those in the control group,with statistical significance(all P<0.05).After treatment,the levels of FEV1,FVC and FEV1/FVC of lung function in the observation group were higher than those in the control group,while the levels of TNF-αand hs-CRP in the observation group were lower than those in the control group,with statistical significance(all P<0.05).Conclusion The combination of drugs has significant therapeutic effect and high safety for COPD patients.
作者
张磊
李维力
王春
ZHANG Lei;LI Weili;WANG Chun(Department of Pharmacy,the Fourth Affiliated Hospital of Anhui Medical University,Anhui Province,Hefei 230012,China;the Hospital Office,Anhui Academy of Science and Technology,Anhui Province,Hefei 230088,China;Institute of Clinical Pharmacology,Anhui Medical University,Anhui Province,Hefei 230032,China)
出处
《中国医药导报》
CAS
2021年第4期90-93,共4页
China Medical Herald
基金
安徽省高校自然科学研究项目(KJ2018A0163)。
关键词
布地奈德混悬液
异丙托溴铵
慢性阻塞性肺疾病
肺功能
炎症水平
Budesonide Suspension
Ipratropium Bromide
Chronic obstructive pulmonary disease
Clinical efficacy
Inflammatory level
